Roth Capital Maintains Buy On NeoGenomics Ahead Of 3Q14 Operating Results On Thursday
In a research report issued today, Roth Capital analyst Debjit Chattopadhyay maintained a Buy rating on NeoGenomics (NASDAQ:NEO) with a $7.00 price target.
Chattopadhyay commented: “Recall that during the quarter NEO made a small tuck-in acquisition of privately held Path Labs, which in our opinion is likely to result in an optically noisy quarter. We anticipate a 350bps QoQ decline in gross margin as NEO integrates the lower margin Path Labs business segment. However, we believe core fundamentals remain strong and recommend buying on any pull back.
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Debjit Chattopadhyay has a total average return of 3.7% and a 33.3% success rate. Chattopadhyay has a 26.3% average return when recommending NEO, and is ranked #1394 out of 3309 analysts.